Day: January 21, 2026

Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026                   Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants Strategic Partnership Discussions Advancing Across Pipeline JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today announced its expected corporate milestones for the first quarter of 2026. “We expect to achieve three important goals during Q1 2026 to drive value for patients with osteoporosis and hypoparathyroidism. We would like to thank the investigators from around...

Next-Generation Functional Beverage Platform Carrying Popular Brands Bucked Up and Ballislife Warwick, NY, Jan. 21, 2026 (GLOBE NEWSWIRE) — Ozop Energy Solutions, Inc. (OZSCD), proudly announces that it has entered into an agreement to acquire Varon Corp, a next-generation functional beverage platform built for culture-driven scale, rapid commercialization, and capital-efficient growth across North America. “This acquisition marks a clear turning point for Ozop,” said Brian Conway, Chief Executive Officer of Ozop Energy Solutions, Inc. “Varon is a growing, revenue-generating beverage company with established brands, embedded cultural distribution, and an experienced management team. By combining Ozop’s public-market structure with Varon’s operating engine, we are repositioning the Company around scalable revenue, disciplined execution,...

SANTA MONICA, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE) (the “Company”), a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, issued a letter to shareholders from the Company’s Chairman and Chief Executive Officer, Matt Edelman. Fellow Shareholders, Over the past ten months, and particularly since completing our financing in October, Super League has undergone a fundamental transformation. What began as a period of stabilization has become a phase of execution. Today, we are operating from a position of strength, clarity, and readiness, building a durable business designed for growth, profitability, and long-term value creation. That progress is beginning to show in our financial performance. We expect the fourth quarter of...

RA’ANANA, Israel, Jan. 21, 2026 (GLOBE NEWSWIRE) — Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today provided an update highlighting significant progress in the execution of its previously announced binding purchase orders. The Company has received a formal notification from its distribution partner that the $22.5 million and $27 million binding purchase orders, originally announced on July 2, 2025 and August 19, 2025, respectively, have advanced to the final budgetary validation and fund allocation stage within the relevant governmental authorities’ procurement processes. According to the notification, approximately 91% of the purchase orders have cleared commercial and administrative...

Highlights vertically integrated waste-to-value platform and 2026 operational milestones HOUSTON, TX, Jan. 21, 2026 (GLOBE NEWSWIRE) — Abundia Global Impact Group, Inc. (NYSE American: AGIG) (“Abundia” or the “Company”), a low-carbon energy solutions company focused on converting biomass and plastics waste into high-value low-carbon fuels, announces it has published an updated investor presentation, which provides a deep dive into Abundia’s core competencies. The Company is focused on delivering a differentiated, vertically integrated waste-to-value platform advancing the renewables economy through implementation of innovative technologies. Led by a team of seasoned executives and operators with proven track records in deploying and scaling across the industrial and energy spaces, Abundia is well positioned to produce low carbon...

-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional target solid tumor and hematologic cancers -Program builds on early clinical evidence of monotherapy activity observed in immune checkpoint inhibitor (CPI)-refractory metastatic melanoma in a previously completed trial CHICAGO and FORT WORTH, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced plans to initiate a Phase 1/2 clinical program evaluating...

Autonomous Security Platforms and Award-Winning SARA Take the Spotlight in Las Vegas Detroit, Michigan, Jan. 21, 2026 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCID:AITX), a global leader in AI-driven security and productivity solutions, along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today confirmed plans to exhibit and present at ISC West, taking place March 23 to 27, 2026 at The Venetian Expo in Las Vegas. RAD will showcase its latest autonomous security platforms at Booth 21117, while CEO Steve Reinharz delivers a featured presentation focused on the future of real time autonomous security response. At ISC West 2026, RAD will present a full lineup of autonomous security solutions including ROAMEO™ Gen 4, RIO™ Mini, ROSA™, AVA™,...

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation, energy security and smart city infrastructure, announced the sale of ten EV ARC™ off-grid electric vehicle (EV) charging systems at a new residential development in New York. This sale reflects the strong customer diversification achieved during 2025, with growing adoption beyond the federal government, including increased demand from commercial customers. This is Beam Global’s largest sale of EV ARC™ systems into a residential development to date and highlights growing demand from commercial and residential property owners seeking alternatives to traditional grid-tied charging infrastructure. The EV ARC™ systems will provide...

MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for gross proceeds of $22.5 million, before deducting commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about January 22, 2026, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by Ocugen. The financing is being led by RTW Investments, with additional participation from new and existing investors. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital...